Discontinued — last reported Q4 '22
Regeneron Pharmaceuticals Change in Deferred Revenue increased by 3312.9% to $99.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 462.7%, from $17.70M to $99.60M. Over 3 years (FY 2021 to FY 2025), Change in Deferred Revenue shows an upward trend with a -24.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase signals strong future revenue potential and customer commitment, while a decrease indicates the fulfillment of prior obligations.
Reflects the change in cash received from customers for goods or services that have not yet been delivered or earned. Th...
Common in technology and equipment sectors with long lead-time contracts.
cf_change_in_deferred_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $78.80M | -$6.40M | -$49.00M | $9.50M | $100.20M | -$17.70M | -$35.90M | -$14.50M | $45.30M | $43.00M | $116.90M | $89.10M | $43.00M | $0.00 | $17.70M | -$142.90M | $76.60M | -$3.10M | $99.60M |
| QoQ Change | — | -108.1% | -665.6% | +119.4% | +954.7% | -117.7% | -102.8% | +59.6% | +412.4% | -5.1% | +171.9% | -23.8% | -51.7% | -100.0% | — | -907.3% | +153.6% | -104.0% | >999% |
| YoY Change | — | — | — | — | +27.2% | -176.6% | -477.9% | -114.5% | +355.9% | — | +425.6% | +714.5% | -5.1% | -100.0% | -84.9% | -260.4% | +78.1% | — | +462.7% |